

Supplementary Material

Competition between phenothiazines and BH3 peptide for the binding site of the antiapoptotic BCL-2 protein


Aline Lagoeiro do Carmo^a, Fernanda Bettanin^b, Michell de Oliveira Almeida^c, Simone Queiroz Pantaleão^a, Tiago Rodrigues^a, Paula Homem-de-Mello^{a,*}, Kathia Maria Honorio^{a,b,*}

^a Centro de Ciências Naturais e Humanas, Universidade Federal do ABC, Santo André, São Paulo, Brazil.


^b Escola de Artes, Ciências e Humanidades, Universidade de São Paulo (USP), São Paulo, Brazil.

^c Instituto de Química de São Carlos, Universidade de São Paulo (USP), São Carlos, São Paulo, Brazil.


*Corresponding author emails: paula.mello@ufabc.edu.br, kmhonorio@usp.br




(a)




(b)




(c)





(d)



(e)

Figure S1. Structures of the compounds which are intended to mimic the BH3 domain that bind to the BH3 binding domain on BCL-2 antiapoptotic members: (a) ABT-737, (b) navitoclax (ABT-263), (c) obatoclax mesylate (GX15-070), (d) venetoclax (ABT-199) and (e) gossypol.




Figure S2. Alignment of human Bcl-2 protein A chain crystallographic structures (PDB_ID: 1YSW, 2O2F, 2O21, 2O22, 2W3L, 4AQ3, 4IEH, 4LVT, 4LXD, 4MAN, 5AGW, 5AGX, 5JSN): (a) left side view; (b) right side view, (c) front view and (d) rear view.

	1	2	3	4	5	6	7	8	9	10	11	12	13
	(1YSW)	(2O2F)	(2O21)	(2O22)	(2W3L)	(4AQ3)	(4IEH)	(4LVT)	(4LXD)	(4MAN)	(5AGW)	(5AGX)	(5JSN)
1	---	1.6	0.0	0.5	1.3	1.3	1.3	1.2	1.3	1.3	1.4	1.4	1.2
2	1.6	---	1.6	1.6	1.6	1.5	1.4	1.4	1.4	1.4	1.6	1.6	1.7
3	0.0	1.6	---	0.5	1.3	1.3	1.3	1.2	1.3	1.3	1.4	1.4	1.2
4	0.5	1.6	0.5	---	1.4	1.3	1.3	1.2	1.3	1.3	1.4	1.5	1.3
5	1.3	1.6	1.3	1.4	---	0.7	1.0	0.7	0.9	0.9	0.8	0.8	0.7
6	1.3	1.5	1.3	1.3	0.7	---	0.8	0.9	0.7	0.8	0.8	0.9	0.8
7	1.3	1.4	1.3	1.3	1.0	0.8	---	0.9	0.5	0.5	0.8	0.9	1.0
8	1.2	1.4	1.2	1.2	0.7	0.9	0.9	---	0.8	0.8	0.9	1.1	0.9
9	1.3	1.4	1.3	1.3	0.9	0.7	0.5	0.8	---	0.5	0.8	0.9	0.9
10	1.3	1.4	1.3	1.3	0.9	0.8	0.5	0.8	0.5	---	0.9	0.9	1.0
11	1.4	1.6	1.4	1.4	0.8	0.8	0.8	0.9	0.8	0.9	---	0.6	0.7
12	1.4	1.6	1.4	1.5	0.8	0.9	0.9	1.1	0.9	0.9	0.6	---	0.9
13	1.2	1.7	1.2	1.3	0.7	0.8	1.0	0.9	0.9	1.0	0.7	0.9	---

Figure S3. RMSD matrix of the alignment of the human Bcl-2 protein A chain crystallographic structures (PDB_ID: 1YSW, 2O2F, 2O21, 2O22, 2W3L, 4AQ3, 4IEH, 4LVT, 4LXD, 4MAN, 5AGW, 5AGX, 5JSN).

1ysw.pdb	1	-HAGRTGYDNR	EIVMKYIHYKLSQR	GYEWD--A--GDDVEENRTEAPEGTESEVVHLTL	54									
2o2f.pdb	1	-----GYDNR	EIVMKYIHYKLSQR	GYEWD-----E-VVHLTL	31									
2o21.pdb	1	-HAGRTGYDNR	EIVMKYIHYKLSQR	GYEWD--A--GDDVEENRTEAPEGTESEVVHLTL	54									
2o22.pdb	1	-HAGRTGYDNR	EIVMKYIHYKLSQR	GYEWD--A--GDDVEENRTEAPEGTESEVVHLTL	54									
2w3l.pdb	1	-----YDNR	EIVMKYIHYKLSQR	GYEWD-----SEVVHLTL	32									
4aq3.pdb	1	-----YDNR	EIVMKYIHYKLSQR	GYEWD-----VVHLAL	29									
4ieh.pdb	1	-----YDNR	EIVMKYIHYKLSQR	GYEWD-----SEVVHLTL	31									
4lvt.pdb	1	-----YDNR	EIVMKYIHYKLSQR	GYEWD--A-----SEVVHLTL	32									
4lxd.pdb	1	R-----TG	YDNR	EIVMKYIHYKLSQR	GYEWDAG-----SEVVHLTL	36								
4man.pdb	1	-----GYDNR	EIVMKYIHYKLSQR	GYE-----EVVHLTL	29									
5agw.pdb	1	-----GYDNR	EIVMKYIHYKLSQR	GYEWD-----SEVVHLTL	32									
5agx.pdb	1	-----GYDNR	EIVMKYIHYKLSQR	GYEWD--A-----SEVVHLTL	33									
5jsn.pdb	1	-----TG	YDNR	EIVMKYIHYKLSQR	GYEWD--ASPV-----PPVVHLTL	37								
			YDNR	EIVMKYIHYKLSQR	GYE	VVHlTL								
1ysw.pdb	55	RQAGDDFSRRYRRDFAEMSSQLH	----LTPFT	ARGRFATVVEELFRDGVNWGRIVAFFEF	110									
2o2f.pdb	32	RQAGDDFSRRYRRDFAEMSSQLHLTPF	----TARGRFATVVEELFRDGVNWGRIVAFFEF		87									
2o21.pdb	55	RQAGDDFSRRYRRDFAEMSSQLH	----LTPFT	ARGRFATVVEELFRDGVNWGRIVAFFEF	110									
2o22.pdb	55	RQAGDDFSRRYRRDFAEMSSQLH	----LTPFT	ARGRFATVVEELFRDGVNWGRIVAFFEF	110									
2w3l.pdb	33	REAGDDFSRRYRRDFAEMSSQLH	----LTPFT	ARGRFATVVEELFRDGVNWGRIVAFFEF	88									
4aq3.pdb	30	RQAGDDFSRRYRRDFAEMSSQLH	----LTPFT	ARGRFATVVEELFRDGVNWGRIVAFFEF	85									
4ieh.pdb	32	RQAGDDFSRRYRRDFAEMSSQLH	----LTPFT	ARGRFATVVEELFRDGVNWGRIVAFFEF	87									
4lvt.pdb	33	RQAGDDFSRRYRRDFAEMSSQLH	----LTPFT	ARGRFATVVEELFRDGVNWGRIVAFFEF	88									
4lxd.pdb	37	RQAGDDFSRRYRRDFAEMSSQLH	----LTPFT	ARGRFATVVEELFRDGVNWGRIVAFFEF	92									
4man.pdb	30	RQAGDDFSRRYRRDFAEMSSQLH	----LTPFT	ARGRFATVVEELFRDGVNWGRIVAFFEF	85									
5agw.pdb	33	RQAGDDFSRRYRRDFAEMSSQLH	----LTPFT	ARGRFATVVEELFRDGVNWGRIVAFFEF	88									
5agx.pdb	34	RQAGDDFSRRYRRDFAEMSSQLH	----LTPFT	ARGRFATVVEELFRDGVNWGRIVAFFEF	89									
5jsn.pdb	38	RQAGDDFSRRYRRDFAEMSSQLH	----LTPFT	ARGRFATVVEELFRDGVNWGRIVAFFEF	93									
		RqAGDDFSRRYRRDFAEMSSQLH		TARGRFATVVEELFRDGVNWGRIVAFFEF										
1ysw.pdb	111	GGVMCVESVNR	EMSP	LV	DNIALW	TEYLN	NRHLHT	WIQD	NGG	WDAFV	ELYG	PSMR	---	164
2o2f.pdb	88	GGVMCVESVNR	EMSP	LV	DNIALW	TEYLN	NRHLHT	WIQD	NGG	WDAFV	ELYG	P	----	138
2o21.pdb	111	GGVMCVESVNR	EMSP	LV	DNIALW	TEYLN	NRHLHT	WIQD	NGG	WDAFV	ELYG	PSMR	---	164
2o22.pdb	111	GGVMCVESVNR	EMSP	LV	DNIALW	TEYLN	NRHLHT	WIQD	NGG	WDAFV	ELYG	PSMR	--	164
2w3l.pdb	89	GGVMCVESVNR	EMSP	LV	DNIALW	TEYLN	NRHLHT	WIQD	NGG	WDAFV	ELYG	PSM	----	141
4aq3.pdb	86	GGVMCVESVNR	EMSP	LV	DNIALW	TEYLN	NRHLHT	WIQD	NGG	WDAFV	ELYG	P	----	135
4ieh.pdb	88	GGVMCVESVNR	EMSP	LV	DNIALW	TEYLN	NRHLHT	WIQD	NGG	WDAFV	ELYG	P	----	138
4lvt.pdb	89	GGVMCVESVNR	EMSP	LV	DNIALW	TEYLN	NRHLHT	WIQD	NGG	WDAFV	ELYG	P	----	139
4lxd.pdb	93	GGVMCVESVNR	EMSP	LV	DNIALW	TEYLN	NRHLHT	WIQD	NGG	WDAFV	ELYG	P	----	143
4man.pdb	86	GGVMCVESVNR	EMSP	LV	DNIALW	TEYLN	NRHLHT	WIQD	NGG	WDAFV	ELYG	P	----	136
5agw.pdb	89	GGVMCVESVNR	EMSP	LV	DNIALW	TEYLN	NRHLHT	WIQD	NGG	WDAFV	ELYG	P	----	139
5agx.pdb	90	GGVMCVESVNR	EMSP	LV	DNIALW	TEYLN	NRHLHT	WIQD	NGG	WDAFV	ELYG	P	----	140
5jsn.pdb	94	GGVMCVESVNR	EMSP	LV	DNIALW	TEYLN	NRHLHT	WIQD	NGG	WDAFV	ELYG	PSMR	LE	149
		GGVMCVESVNR	EMSP	LV	DNIALW	TEYLN	NRHLHT	WIQD	NGG	WDAFV	ELYG			

Figure S4. Alignment of A-chain crystallographic structures of human Bcl-2 protein (PDB_ID: 1YSW, 2O2F, 2O21, 2O22, 2W3L, 4AQ3, 4IEH, 4LVT, 4LXD, 4MAN, 5AGW, 5AGX, 5JSN), representing hydrophobic residues including aromatics (red), acids (blue), basic (pink) and basic with hydroxyl groups and / or amino groups (green); with the marking line below each stretch of the multiple alignment indicating fully conserved residues (upper case) and partially conserved residues (lower case).

Table S1. Characteristics of probes used by FTSite and FTMap servers

Probe	Properties^a
Acetamide (ACD)	Polar, hydrogen bond acceptor and donor
Acetonitrile (ACN)	Polar and hydrogen bond acceptor character
Acetone (ACT)	Polar and hydrogen bond acceptor character
Acetaldehyde (ADY)	Polar and hydrogen bond acceptor character
Methylamine (AMN)	Polar, hydrogen bond acceptor and donor
Benzaldehyde (BDY)	Polar, aromatic and hydrogen bond acceptor character
Benzene (BEN)	Hydrophobic and aromatic
Butanol (BUT)	Polar and hydrogen bond acceptor character
Ciclohexane (CHX)	Polar, hydrogen bond acceptor and donor
N,N-dimethylformamide (DFO)	Polar and hydrogen bond acceptor character
Dimethyl ether (DME)	Polar and hydrogen bond acceptor character
Ethanol (EOL)	Polar, hydrogen bond acceptor and donor
Ethane (ETH)	Hydrophobic
Phenol (PHN)	Polar, aromatic, hydrogen bond acceptor and donor
Isopropanol (THS)	Polar and hydrogen bond acceptor character
Urea (URE)	Polar, hydrogen bond acceptor and donor

(a) (Bohnuud et al. 2012; Brenke et al. 2009; D. Kozakov et al. 2011; Dima Kozakov et al. 2015; Ngan et al. 2012)

Table S2. Hydrophobicity and hydrophilicity values by Kyte and Doolittle

Residues	Kyte-Doolittle Values ^a	Classifications	Color Scale ^c
Ile	4.5	Hydrophobic	Orange-red
Val	4.2	Hydrophobic	Orange-red
Leu	3.8	Hydrophobic	Orange-red
Phe	2.8	Hydrophobic	Orange-red
Cys	2.5	Hydrophobic	Orange-red
Met	1.9	Hydrophobic	Orange-red
Ala	1.8	Hydrophobic	Orange-red
Gly	-0.4	Neutral	White
Thr	-0.7	Neutral	White
Ser	-0.8	Neutral	White
Trp	-0.9	Neutral	White
Tyr	-1.3	Neutral	White
Pro	-1.6	Neutral	White
His	-3.2	Hydrophilic	Blue
Glu	-3.5	Hydrophilic	Blue
Gln	-3.5	Hydrophilic	Blue
Asp	-3.5	Hydrophilic	Blue
Asn	-3.5	Hydrophilic	Blue
Lys	-3.9	Hydrophilic	Blue
Arg	-4.5	Hydrophilic	Blue

(a) Kyte and Doolittle, 1982.

(b) De Oliveira Rodrigues et al., 2015.

(c) Pettersen et al., 2004.




Figure S5. Representation of the molecular coupling of the ligand at the original position of the protein-ligand complex crystal structure (light pink) (PDB_ID: 2O22) and ligand overlap (Blue).




Figure S6. Interactions Predicted by the Poseview Server. (a) crystallographic ligand pose (PDB_ID: 2O22) and (b) ligand pose obtained from re-coupling.






Figure S7. (a) Representation of BH1-BH4 domains (Figure 2) with presence of site 2 detected by FTSite server with aliphatic chlorpromazine subclass molecular coupling, ($EC_{50} = (125.3 \pm 1.1) \mu\text{mol.L}^{-1}$) performed on the AutoDock Vina 1.5.7 program. Representation of the π -stacking (green), hydrogen bonding (red) and saline bridge (Blue) interaction of the molecular couplings performed in AutoDock Vina 1.5.7 (b) and Achilles Blind Docking (c) server, with additional interactions and / or confirmed by the BINANA 1.2.0 algorithm.




Figure S8. (a) Representation of BH1-BH4 domains (Figure 2) with the presence of site 2 detected by the FTSite server with the aliphatic subclass triflupromazine molecular coupling ($EC_{50} = (105.9 \pm 1.0) \mu\text{mol}\cdot\text{L}^{-1}$) performed in the AutoDock Vina 1.5.7 program. Representation of π -stacking (green), cation- π (yellow) and hydrogen bonding (red) interactions of the molecular couplings performed in AutoDock Vina 1.5.7 (b) and Achilles Blind Docking (c) server, with interactions additional and / or confirmed by the BINANA 1.2.0 algorithm.






Figure S9. (a) Representation of BH1-BH4 domains (Figure 2) with presence of site 2 detected by FTSite server with piperazine subclass molecular coupling of fluphenazine ($EC_{50} = (63.2 \pm 1.0) \mu\text{mol.L}^{-1}$) performed in the AutoDock Vina 1.5.7 program. Representation of π -stacking (green), cation- π (yellow) and hydrogen bonding (red) interactions of the molecular couplings performed in AutoDock Vina 1.5.7 (b) and Achilles Blind Docking (c) server, with interactions additional and / or confirmed by the BINANA 1.2.0 algorithm.




Figure S10. (a) Representation of BH1-BH4 domains (Figure 2) with the presence of site 2 detected by the FTSite server with the piperazine subclass trifluoperazine molecular coupling ($EC_{50} = (56.2 \pm 1.0) \mu\text{mol.L}^{-1}$) performed in the AutoDock Vina 1.5.7 program. Representation of the π -stacking (green), hydrogen bonding (red) and saline bridge (Blue) interaction of the molecular couplings performed in AutoDock Vina 1.5.7 (b) and Achilles Blind Docking (c) server, with additional interactions and / or confirmed by the BINANA 1.2.0 algorithm.




Figure S11. Representation of the molecular coupling of peptide BH3 in the original position of the crystalline structure (blue) (PDB_ID: 2XA0) in relation to the composition used by the coupling (orange) with the GalaxyPepDock server (RMSD 1.962 Å between the alpha helix amino acid residues).




Figure S12. RMSD values of BCL-2 in Apo form (black), BCL-2 with trifluoperazine molecule (red) and 3D conformation obtained by clustering the MD.




Figure S13. RMSD values of BCL-2 in Apo form (black), BCL-2 with fluphenazine molecule (red) and 3D conformation obtained by clustering the MD.






Figure S14. RMSD values of BCL-2 in Apo form (black), BCL-2 with trifluopromazine molecule (red) and 3D conformation obtained by clustering the MD.




Bcl-2 with Chlorpromazine




— Apo Form — Bcl-2 with Chlorpromazine

Figure S15. RMSD values of BCL-2 in Apo form (black), BCL-2 with chlorpromazine molecule (red) and 3D conformation obtained by clustering the MD.





— Apo Form — Bcl-2 with Trifluoperazine



— Apo Form — Bcl-2 with Trifluoperazine



Figure S16. RMSF values of BCL-2 in the presence of trifluoperazine.



— Apo Form — Bcl-2 with Flufenazine

— Apo Form — Bcl-2 with Flufenazine



Figure S17. RMSF values of BCL-2 in the presence of fluphenazine.



— Apo Form — Bcl-2 with Trifluopromazine

— Apo Form — Bcl-2 with Trifluopromazine

Figure S18. RMSF values of BCL-2 in the presence of trifluopromazine.



— Apo Form — Bcl-2 with Chlorpromazine

— Apo Form — Bcl-2 with Chlorpromazine

Figure S19. RMSF values of BCL-2 in the presence of chlorpromazine.

REFERENCES

- Bohnuud, Tanggis et al. 2012. "Computational Mapping Reveals Dramatic Effect of Hoogsteen Breathing on Duplex DNA Reactivity with Formaldehyde." *Nucleic Acids Research* 40(16): 7644–52. <https://academic.oup.com/nar/article/40/16/7644/1032290>.
- Brenke, Ryan et al. 2009. "Fragment-Based Identification of Druggable 'Hot Spots' of Proteins Using Fourier Domain Correlation Techniques." *Bioinformatics* 25(5): 621–27. <https://academic.oup.com/bioinformatics/article-lookup/doi/10.1093/bioinformatics/btp036>.
- Kozakov, D. et al. 2011. "Structural Conservation of Druggable Hot Spots in Protein-Protein Interfaces." *Proceedings of the National Academy of Sciences* 108(33): 13528–33. <http://www.pnas.org/cgi/doi/10.1073/pnas.1101835108>.
- Kozakov, Dima et al. 2015. "The FTMap Family of Web Servers for Determining and Characterizing Ligand-Binding Hot Spots of Proteins." *Nature Protocols* 10(5): 733–55. <http://www.nature.com/articles/nprot.2015.043>.
- Kyte, Jack, and Russell F. Doolittle. 1982. "A Simple Method for Displaying the Hydrophobic Character of a Protein." *Journal of Molecular Biology* 157(1): 105–32. <https://linkinghub.elsevier.com/retrieve/pii/0022283682905150>.
- Ngan, Chi-Ho et al. 2012. "FTSite: High Accuracy Detection of Ligand Binding Sites on Unbound Protein Structures." *Bioinformatics* 28(2): 286–87. <https://academic.oup.com/bioinformatics/article-lookup/doi/10.1093/bioinformatics/btr651>.
- De Oliveira Rodrigues, Thiago Assis, Larissa Fernandes Leijôto, Poliane C. Oliveira Brandão, and Cristiane Neri Nobre. 2015. "Predição de Função de Proteínas Através Da Extração de Características Físico-Químicas." *Revista de Informática Teórica e Aplicada* 22(1): 29. <http://seer.ufg.br/index.php/rita/article/view/RITA-VOL22-NR1-29>.
- Pettersen, Eric F. et al. 2004. "UCSF Chimera?A Visualization System for Exploratory Research and Analysis." *Journal of Computational Chemistry* 25(13): 1605–12. <http://doi.wiley.com/10.1002/jcc.20084>.